Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

A Global Alliance Established for Sharing Genomic Data

By BiotechDaily International staff writers
Posted on 24 Jun 2013
A shared framework for analyzing and distributing genomic information should soon speed medical progress and innovations.

Nearly 70 organizations in research, healthcare, and disease advocacy have agreed to take part in a global alliance focused on standardizing and sharing genomic and clinical data. “The cost of genome sequencing has fallen one-million fold in the past several years, fueling an explosion of information about the genetic basis of human health and disease,” wrote the authors of a white report announcing the alliance. In principle, this plethora of genome data could reveal the genetic basis of inherited and infectious disease, cancer, and drug responses. “However, we are not organized to seize this extraordinary opportunity.”

The problem is that the data are “collected and studied in silos: by disease, by institution, and by country,” reported the investigators. Tools and techniques for study are not standardized and can be incompatible. Furthermore, there are not agreed upon regulatory procedures that respect the privacy of people who have donated their genome sequences to research projects. All this “inhibits learning and improving healthcare,” they reported.

To address these problems, the alliance will develop international standards and infrastructure to share and integrate data in a controlled, secure, and interpretable way that upholds patient autonomy and right to privacy. Participants in the accord include the US National Institutes of Health (Bethesda, MD, USA), the Wellcome Trust Sanger Institute (Hinxton, Cambridgeshire, UK), and the Beijing Genomics institute (BGI; Beijing, China), as well as universities and hospitals.

The large pool of genomic sequences and medical data expected from the alliance is the sort of dataset required to determine the genetic basis of both cancer and rare diseases, recently reported an item in the New York Times. The mutations underlying these disorders are just too rare to be studied in data collected at a single institution.

A disease might occur in one in 1,000 or one in 100,000 babies, according to Dr. David Altshuler, deputy director and chief academic officer at the Broad Institute of Harvard University (Cambridge, MA, USA) and the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA). A medical center might never see a child with that disease, or might see just one. “Since everyone sees zero or one, no one ever learns,” Dr. Altshuler said.

In spite of the commendable goals of the alliance, researchers may be reluctant to share hard-won genomic information, a “valuable commodity,” the researcher noted. A big question for the group is whether it can convince institutions to share their most meaningful data. “The mission is unquestionably worthy,” said cardiologist Dr. Eric Topol, director of the Scripps Translational Science Institute (La Jolla, CA, USA), which has not yet considered joining the alliance. But, he adds, “it means taking the walls down, and that’s tricky—because you’ve got each center wanting to hold on to its own data, and the loss of control is a very difficult concept.”

Related Links:
US National Institutes of Health
Wellcome Trust Sanger Institute
Massachusetts Institute of Technology



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.